Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Sullivan-B?lyai JZ, Allen LB, Cannon R, Cohane KP, Dunzo E, Goldwater R, StCyr K, Wang Y, Klempner MS. A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (S315) Against Diphtheria Toxin. J Infect Dis. 2025 Sep 15; 232(3):534-539.
-
Treverton J, Arnold DM, Ivanov DG, Ivetic N, Zhang Y, Ali HA, Clare R, Kaltashov IA, Kelton JG, Nazy I. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. N Engl J Med. 2025 Sep 04; 393(9):879-886.
-
Rudolph MJ, Muriuki BM, Chen Y, Vance DJ, Vorauer C, Piazza CL, Freeman-Gallant G, Golonka RM, Mirabile G, Guttman M, Cavacini LA, Mantis NJ. Germline encoded residues dominate the interaction of a human monoclonal antibody with decorin binding protein A of Borrelia burgdorferi. Front Immunol. 2025; 16:1611828.
-
Grace PS, Peters JM, Sixsmith J, Lu R, Irvine EB, Luedeman C, Fenderson BA, Vickers A, Slein MD, McKitrick T, Wei MH, Cummings RD, Wallace A, Cavacini LA, Choudhary A, Proulx MK, Sundling C, K?llenius G, Reljic R, Ernst JD, Casadevall A, Locht C, Pinter A, Sassetti CM, Bryson BD, Fortune SM, Alter G. Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction. Immunity. 2025 Jun 10; 58(6):1586-1597.e5.
-
Rodriguez-Otero P, Voorhees PM, Boccadoro M, Laubach J, Einsele H, Sborov DW, Dimopoulos MA, Broijl A, Mina R, Spencer A, Schjesvold F, Silbermann R, Gay F, Costa LJ, Perrot A, Liu Y, Wang J, Sitthi-Amorn A, Carson R, Cortoos A, Usmani SZ, Richardson PG, Moreau P, Sonneveld P, Kaufman JL. Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged =65 years from GRIFFIN and PERSEUS. Clin Lymphoma Myeloma Leuk. 2025 Oct; 25(10):746-758.e6.
-
Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 2025 Mar 19; 26(1):96.
-
Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
-
Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L, Talpes M, Majer I, Patel S, Usmani SZ. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial. Clin Lymphoma Myeloma Leuk. 2025 Aug; 25(8):590-605.
-
Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang G, Gupta-Werner N, Kaila S, Pei H, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. Eur J Haematol. 2025 May; 114(5):883-889.
-
Vance DJ, Freeman-Gallant G, McCarthy K, Piazza CL, Chen Y, Vorauer C, Muriuki B, Rudolph MJ, Cavacini L, Guttman M, Mantis NJ. A type-specific B-cell epitope at the apex of outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi. Microbiol Spectr. 2025 Apr; 13(4):e0288324.